Covid-19

Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
Teresa Po-Yu Chiang, Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Jennifer L Alejo, William A Werbel, Allan Massie, Lisa Christopher-Stine, Jacqueline Garonzik-Wang, Dorry L Segev, Julie J Paik

Annals of the Rheumatic Diseases Oct 2021, 80 (10) 1365-1366; DOI: 10.1136/annrheumdis-2021-221145
Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’
Serena Bugatti, Silvia Balduzzi, Ludovico De Stefano, Antonio Manzo, Blerina Xoxi, Laura Bogliolo, Sara Monti, Paolo Delvino, Carlomaurizio Montecucco

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e156; DOI: 10.1136/annrheumdis-2021-220541
Response to: ‘Correspondence on ‘EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs’’ by Bugatti et al
Johannes W J Bijlsma

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e157; DOI: 10.1136/annrheumdis-2021-220564
Correspondence on ‘Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Chiara Salviani, Francesco Scolari, Federico Alberici

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e158; DOI: 10.1136/annrheumdis-2021-220496
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Giuseppe A Ramirez, Emanuel Della-Torre, Luca Moroni, Mona-Rita Yacoub, Lorenzo Dagna

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e159; DOI: 10.1136/annrheumdis-2021-220539
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Jesse Veenstra, Jie Wang, Kathleen McKinnon-Maksimowicz, Tingting Liu, Bobby Zuniga, Iltefat Hamzavi, Li Zhou, Qing-Sheng Mi

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e160; DOI: 10.1136/annrheumdis-2021-220736
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
Larissa Valor-Méndez, Koray Tascilar, David Simon, Joerg Distler, Arnd Kleyer, Georg Schett, Juergen Rech

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e161; DOI: 10.1136/annrheumdis-2021-220898
Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’
Timm H Westhoff, Felix S Seibert, Moritz Anft, Arturo Blazquez-Navarro, Sarah Skrzypczyk, Adrian Doevelaar, Bodo Hölzer, Krystallenia Paniskaki, Sebastian Dolff, Benjamin Wilde, Oliver Witzke, Juergen Braun, Ulrik Stervbo, Nina Babel

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e162; DOI: 10.1136/annrheumdis-2021-220756
Response to: ‘Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’’ by Westhoff et al
Michael Bonelli, Daniel Aletaha

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e163; DOI: 10.1136/annrheumdis-2021-220764
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Caoilfhionn Marie Connolly, Darya Koenig, Srekar N Ravi, Antoine Azar, Sam Kant, Monika Dalal, Jessica Duchen, Philip Seo, Brendan Antiochos, Julie J Paik, Duvuru Geetha

Annals of the Rheumatic Diseases Oct 2021, 80 (10) e164; DOI: 10.1136/annrheumdis-2021-220972

Main menu

Covid-19

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Covid-19

Pages